Comprehensive Report on MGL-3196 (Resmetirom/Rezdiffra): A Novel Thyroid Hormone Receptor-Beta Agonist

1. Executive Summary

MGL-3196, now known by the generic name Resmetirom and marketed as Rezdiffra, is a first-in-class, orally administered, once-daily, liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist.[1] It has recently achieved a significant regulatory milestone with accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with noncirrhotic non-alcoholic steatohepatitis (NASH) characterized by moderate to advanced liver fibrosis (stages F2 to F3), to be used in conjunction with diet and exercise.[4] This approval addresses a critical unmet medical need, as NASH is a prevalent and progressive liver disease that previously lacked any FDA-approved pharmacological therapies.[5]

The clinical development program for Resmetirom, notably the MAESTRO-NASH trial, has provided evidence of its efficacy in achieving key histological endpoints, including NASH resolution without worsening of fibrosis and improvement in fibrosis stage by at least one stage without worsening of NASH, at 52 weeks of treatment.[7] Beyond its direct effects on liver histology, Resmetirom has also demonstrated beneficial effects on atherogenic lipid profiles. Significant reductions in low-density lipoprotein cholesterol (LDL-C), triglycerides, and other atherogenic lipoproteins have been observed in NASH clinical trials and further substantiated in trials conducted in patients with Heterozygous Familial Hypercholesterolemia (HeFH).[10]

The mechanism of action of Resmetirom is centered on its selective agonism of THR-β, which is predominantly expressed in the liver.[1] This selectivity is designed to harness the metabolic benefits of thyroid hormone signaling within the liver—such as increased fatty acid oxidation and reduced de novo lipogenesis—while minimizing potential systemic adverse effects associated with THR-alpha (THR-α) activation, which is more prevalent in tissues like the heart and bone.[2]

The safety profile of Resmetirom is generally considered manageable. The most commonly reported adverse events in clinical trials are transient gastrointestinal disturbances, primarily diarrhea and nausea, often occurring at the initiation of therapy.[4] However, the prescribing information includes important warnings regarding the potential for hepatotoxicity and gallbladder-related adverse reactions, underscoring the need for careful patient monitoring during treatment.[6] Furthermore, potential drug-drug interactions, particularly with statins (requiring dose limitations) and inhibitors of the CYP2C8 enzyme (which metabolizes Resmetirom), necessitate clinical vigilance and appropriate management.[6]

The advent of Rezdiffra represents a paradigm shift in the therapeutic landscape for NASH.[5] Previously, management relied on lifestyle interventions and off-label use of medications primarily indicated for other conditions. The availability of an approved, targeted therapy provides a new standard of care and is expected to stimulate further research and development in this complex disease area. The dual benefit of improving both liver histology and the cardiometabolic risk profile is a particularly compelling aspect of Resmetirom's clinical profile, given the high prevalence of cardiovascular comorbidities in NASH patients.[10] However, the accelerated nature of its FDA approval, based on surrogate histological endpoints, places considerable importance on the outcomes of ongoing confirmatory trials, such as MAESTRO-NASH OUTCOMES. These long-term studies are crucial for verifying the anticipated clinical benefits, including the prevention of progression to cirrhosis, liver decompensation, and other severe liver-related events.[2]

2. Drug Profile: MGL-3196 (Resmetirom)

MGL-3196, which has progressed through clinical development to become Resmetirom (Rezdiffra), is a novel therapeutic agent targeting metabolic liver disease.

Nomenclature:

The compound was initially identified by its investigational name, MGL-3196.2 Upon further development, it was assigned the generic name Resmetirom.1 For commercialization, it is marketed under the brand name Rezdiffra.4 An alternative synonym, VIA-3196, has also been noted in some literature.15

DrugBank ID:

Resmetirom is cataloged in the DrugBank database with the unique identifier DB12914.1

Chemical Class and Type:

Resmetirom is classified as a Small Molecule drug.1 Its chemical structure is complex, and its IUPAC (International Union of Pure and Applied Chemistry) name is 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile.14 This nomenclature indicates key structural features, including a dichlorophenyl moiety, a dihydropyridazinone ring, and a tetrahydro-1,2,4-triazine-6-carbonitrile system. These structural elements are integral to its interaction with the target receptor and its pharmacological properties. The specific arrangement and nature of these chemical groups are believed to be fundamental to its high binding affinity and, critically, its selectivity for the THR-β isoform over the THR-α isoform. This engineered molecular specificity is a cornerstone of its therapeutic strategy, aiming to concentrate its metabolic benefits within the liver while minimizing the potential for off-target effects commonly associated with less selective thyroid hormone analogues, such as those impacting cardiac function or bone metabolism.

CAS Number:

The Chemical Abstracts Service (CAS) registry number assigned to Resmetirom is 920509-32-6.14

Molecular Formula and Weight:

The molecular formula of Resmetirom is C17​H12​Cl2​N6​O4​.14 This corresponds to a molecular weight of approximately 435.22 g/mol.14

Developer:

Resmetirom (marketed as Rezdiffra) was developed by Madrigal Pharmaceuticals, Inc..2

Inactive Ingredients:

The tablet formulation of Rezdiffra contains several inactive ingredients, which include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose.25 These excipients are commonly used in pharmaceutical formulations to aid in manufacturing, stability, and drug delivery.

Table 1: MGL-3196 (Resmetirom/Rezdiffra) - Key Drug Information

Feature	Details
Investigational Name	MGL-3196
Generic Name	Resmetirom
Brand Name	Rezdiffra
Other Synonyms	VIA-3196
DrugBank ID	DB12914
CAS Number	920509-32-6
Type	Small Molecule
Chemical Class	1,2,4-triazine derivative / Pyridazine derivative
Developer	Madrigal Pharmaceuticals, Inc.
FDA Approved Indication	Indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

This table consolidates the fundamental identification and classification details of Resmetirom, providing a quick reference essential for a comprehensive understanding of the drug. It synthesizes information from various sources [1] into an easily digestible format, laying the groundwork for the subsequent detailed pharmacological and clinical discussion.

3. Mechanism of Action

Resmetirom's therapeutic effects are primarily mediated through its selective agonism of the thyroid hormone receptor-beta (THR-β), a nuclear receptor that plays a critical role in regulating metabolic processes, particularly in the liver.

Selective Thyroid Hormone Receptor-Beta (THR-β) Agonism:

Resmetirom is an orally active, partial agonist of THR-β.2 A key characteristic of Resmetirom is its significant selectivity for the THR-β isoform over THR-α. Compared to the endogenous thyroid hormone triiodothyronine (T3), Resmetirom exhibits approximately 28-fold greater selectivity for THR-β.2 This isoform specificity is crucial because THR-β is predominantly expressed in the liver, the primary target organ for Resmetirom's action in NASH.1 In contrast, THR-α is more widely distributed, with significant expression in the heart and bone. By preferentially activating THR-β, Resmetirom aims to deliver the beneficial metabolic effects of thyroid hormone signaling within the liver while minimizing the potential for undesirable systemic effects, such as cardiac arrhythmias or bone demineralization, which are often associated with THR-α activation by non-selective thyroid hormone analogues.2 In vitro functional assays have quantified Resmetirom's activity, demonstrating that it produces 83.8% of the maximum response compared to T3 at the THR-β receptor, with a half maximal effective concentration (EC50) of 0.21 µM for THR-β activation.14

Liver-Directed Effects and Rationale in NASH:

Resmetirom is characterized as a liver-directed compound.1 This hepatoselectivity is thought to arise from a combination of factors, including efficient uptake into hepatocytes via specific transporter mechanisms (such as Organic Anion Transporting Polypeptide 1B1, OATP1B1) and its intrinsic preferential binding and activation of THR-β over THR-α within these cells.14

A significant pharmacological advantage of Resmetirom is its insensitivity to deiodinase enzymes.[2] Endogenous thyroid hormones (T4 and T3) are subject to metabolism by deiodinases within the liver, which can convert T4 to the more active T3 or inactivate both T3 and T4. This enzymatic activity regulates local thyroid hormone concentrations. Resmetirom's resistance to deiodinase action means its concentration and activity within the liver are less likely to be diminished by this metabolic pathway, potentially leading to more sustained and predictable target engagement compared to natural thyroid hormones. This stability contributes to its suitability for once-daily oral administration and consistent therapeutic effects.

The therapeutic rationale for employing a THR-β agonist in NASH is underpinned by growing evidence suggesting that a state of "liver-specific hypothyroidism" or impaired THR-β signaling may contribute to the pathogenesis of NAFLD and NASH, particularly in individuals with more advanced disease.[1] Studies have indicated that hepatic THR-β mRNA expression is inversely correlated with the histological severity of NASH.[10] Resmetirom aims to directly address this apparent deficiency in hepatic thyroid hormone signaling, suggesting a mechanism that targets a fundamental metabolic dysregulation within the liver rather than merely alleviating downstream symptoms.

Impact on Lipid Metabolism and Hepatic Steatosis:

Upon binding to and activating THR-β in hepatocytes, Resmetirom initiates a cascade of transcriptional events that favorably modulate lipid metabolism.3 Its primary effect in combating NASH is the reduction of hepatic steatosis (fat accumulation) through multiple synergistic actions 1:

• Enhanced Fat Catabolism: It promotes lipophagy, the autophagic degradation of intracellular lipid droplets, effectively clearing stored fats.
• Improved Mitochondrial Function: Resmetirom stimulates mitochondrial biogenesis (the formation of new mitochondria) and mitophagy (the selective removal of damaged or dysfunctional mitochondria). This leads to an overall improvement in mitochondrial health and an increased capacity for hepatic fatty acid β-oxidation, thereby reducing the burden of lipotoxic lipid species that drive liver injury in NASH.
• Reduced De Novo Lipogenesis (DNL): It curtails the synthesis of new fatty acids in the liver by suppressing the expression of key lipogenic transcription factors, notably sterol regulatory element binding protein-1c (SREBP-1c).[10]
• Cholesterol Homeostasis: Resmetirom enhances cholesterol metabolism, in part by upregulating the expression of cytochrome P450 7A1 (CYP7A1), the rate-limiting enzyme in the classical pathway of bile acid synthesis from cholesterol.[10]
• Increased LDL Uptake: It promotes the clearance of LDL-cholesterol from the circulation by increasing its uptake into the liver.[1]

Anti-inflammatory and Anti-fibrotic Effects:

While the primary effects are on lipid metabolism, Resmetirom also appears to exert beneficial effects on liver inflammation and fibrosis, two other critical components of NASH progression. It is suggested to possess anti-inflammatory properties by modulating the expression of genes involved in hepatic inflammatory pathways.3 Furthermore, clinical and preclinical evidence indicates its potential to reduce liver fibrosis, possibly by influencing the expression of genes directly involved in the fibrogenic process, such as those related to hepatic stellate cell activation and extracellular matrix deposition.1 This multifaceted mechanism, targeting steatosis, inflammation, and fibrosis, likely underpins its observed efficacy in achieving both NASH resolution and fibrosis regression.

4. Pharmacological Profile

4.1 Pharmacodynamics

Resmetirom exhibits a range of pharmacodynamic effects that contribute to its therapeutic utility in NASH and related metabolic disorders.

Effects on Liver Fat and Histology:

A primary pharmacodynamic effect of Resmetirom is the significant reduction of hepatic fat content. This has been consistently demonstrated in clinical trials using non-invasive imaging techniques such as Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF).1 The underlying mechanisms for this fat reduction include the promotion of lipophagy, enhancement of mitochondrial biogenesis and mitophagy (leading to improved mitochondrial function and turnover), and stimulation of hepatic fatty acid β-oxidation.1 Preclinical studies in animal models of NASH have corroborated these findings, showing that Resmetirom treatment leads to reductions in liver weight, amelioration of hepatic steatosis, and improvements in the overall NAFLD Activity Score (NAS).14

Impact on Serum Lipids:

Resmetirom has a pronounced beneficial impact on atherogenic lipid profiles. Clinical studies have consistently shown significant reductions in:

• Low-density lipoprotein cholesterol (LDL-C).[1]
• Serum triglycerides.[2]
• Apolipoprotein B (ApoB), the main structural protein of LDL particles.[11]
• Lipoprotein(a) (Lp(a)), an independent and genetically determined risk factor for cardiovascular disease.[10] These lipid-modifying effects are particularly relevant given the increased cardiovascular risk in NASH patients and suggest a potential for Resmetirom to offer cardioprotective benefits beyond its direct actions on the liver.

Effects on Liver Enzymes and Biomarkers of Fibrosis:

Treatment with Resmetirom leads to reductions in elevated serum levels of liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes are released from damaged hepatocytes, and their reduction indicates an amelioration of ongoing liver injury.1 Furthermore, Resmetirom has been shown to improve various non-invasive markers associated with liver fibrogenesis and to decrease liver stiffness, as assessed by techniques like transient elastography (FibroScan).1

Other Pharmacodynamic Effects:

A key aspect of Resmetirom's pharmacodynamic profile, highlighting its THR-β selectivity, is that it generally does not cause clinically significant changes in thyroid-stimulating hormone (TSH) levels. This indicates a lack of undesirable feedback on the hypothalamic-pituitary-thyroid axis. Additionally, studies have not typically shown adverse effects on bone mineral density or key cardiovascular markers (such as heart rate or blood pressure), which can be concerns with non-selective thyroid hormone mimetics.10 In preclinical models of diet-induced obesity (DIO), Resmetirom has also demonstrated the ability to lower plasma glucose levels and improve insulin sensitivity 15, suggesting broader positive metabolic effects.

4.2 Pharmacokinetics

The pharmacokinetic profile of Resmetirom supports its once-daily oral administration.

Absorption:

Resmetirom is administered orally, typically as a once-daily dose.1 Following multiple daily doses of 80 mg or 100 mg, the median time to reach maximum plasma concentration (Tmax) is approximately four hours.22 The presence of food can influence its absorption kinetics; concomitant administration with food resulted in a 33% decrease in Cmax, an 11% decrease in overall exposure (Area Under the Curve, AUC), and a delay in median Tmax by about two hours. Despite these food-induced alterations, the prescribing information states that Rezdiffra can be administered with or without food, suggesting that these changes do not critically impair its clinical efficacy or overall exposure to a degree that necessitates strict fasting or co-administration with meals.6 This flexibility can enhance patient convenience and adherence.

Distribution:

The apparent volume of distribution (Vd/F) of Resmetirom at steady-state is 68 liters, indicating that the drug distributes beyond the plasma compartment into tissues.22 Consistent with its mechanism of action, Resmetirom is liver-directed. Preclinical data from studies in mice with diet-induced obesity demonstrated a liver-to-plasma concentration ratio of 8:1, supporting its preferential accumulation and action in the target organ.15

Metabolism:

Resmetirom is primarily metabolized by the cytochrome P450 enzyme CYP2C8.6 This specific metabolic pathway is a crucial consideration for potential drug-drug interactions. Co-administration with strong or moderate inhibitors of CYP2C8 (such as gemfibrozil or clopidogrel, respectively) can significantly increase Resmetirom exposure, necessitating dose adjustments or avoidance as outlined in the prescribing information.6

Excretion:

Detailed information regarding the specific routes (e.g., renal versus fecal) and quantitative percentages of excretion for Resmetirom and its metabolites is not extensively covered in the provided research snippets. Such information is vital for a complete pharmacokinetic understanding, particularly for guiding dosage in patients with significant renal or hepatic impairment beyond the NASH indication itself.

Dosing and Administration:

The FDA-approved dosage of Rezdiffra is determined by the patient's actual body weight. For patients weighing less than 100 kg (220 lbs), the recommended dosage is 80 mg orally once daily. For patients weighing 100 kg or more, the recommended dosage is 100 mg orally once daily.6 As noted, Rezdiffra can be administered with or without food.6 The weight-based dosing strategy likely aims to achieve optimal therapeutic exposure across different patient sizes, balancing efficacy and tolerability.

The metabolism via CYP2C8 is a critical pharmacokinetic characteristic that has direct implications for prescribing practices. NASH patients often present with multiple comorbidities such as diabetes, hypertension, and dyslipidemia, leading to polypharmacy. The potential for interactions with CYP2C8 inhibitors, which could elevate Resmetirom levels and potentially increase the risk of adverse effects, requires clinicians to perform thorough medication reviews and adhere to dose modification guidelines when necessary.

Table 6: Key Pharmacokinetic Parameters of Resmetirom

Parameter	Value / Description
Administration	Oral, once-daily
Tmax (multiple doses)	Approximately 4 hours 22
Effect of Food	Cmax ↓33%, AUC ↓11%, Tmax delayed ~2 hours. Can be taken with or without food.6
Volume of Distribution (Vd/F)	68 L 22
Metabolism	Primarily via CYP2C8 6
Key Drug Interactions	Moderate and Strong CYP2C8 inhibitors (e.g., clopidogrel, gemfibrozil). Statins (e.g., atorvastatin, rosuvastatin).6

This table summarizes crucial pharmacokinetic properties that influence dosing regimens, the potential for drug interactions, and patient counseling. It provides clinicians with a concise overview of how Resmetirom behaves in the body and how its administration should be managed.

5. Clinical Development and Efficacy

Resmetirom has undergone extensive clinical development, primarily focusing on its efficacy and safety in Non-alcoholic Steatohepatitis (NASH) and also exploring its lipid-lowering effects in Heterozygous Familial Hypercholesterolemia (HeFH).

5.1 Non-alcoholic Steatohepatitis (NASH)

The MAESTRO clinical trial program, sponsored by Madrigal Pharmaceuticals, forms the cornerstone of Resmetirom's development for NASH. This program includes several Phase 3 studies: MAESTRO-NASH, MAESTRO-NAFLD-1, its open-label extension MAESTRO-NAFLD-OLE, and the long-term outcomes study, MAESTRO-NASH-OUTCOMES.[2]

Pivotal Phase 3 MAESTRO-NASH Trial (NCT03900429):

The MAESTRO-NASH trial is a multinational, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of Resmetirom in adult patients with biopsy-confirmed NASH and significant liver fibrosis (stages F1B, F2, or F3, where fibrosis stages range from F0 [no fibrosis] to F4 [cirrhosis]).2 Participants were randomized in a 1:1:1 ratio to receive once-daily oral Resmetirom at a dose of 80 mg, Resmetirom 100 mg, or placebo.7 The primary analysis population comprised 966 patients: 322 in the 80-mg Resmetirom group, 323 in the 100-mg Resmetirom group, and 321 in the placebo group, with balanced baseline characteristics across the arms.2

The co-primary endpoints, assessed at 52 weeks via liver biopsy, were:

1. NASH resolution (defined as achieving a hepatocellular ballooning score of 0, a lobular inflammation score of 0 or 1, and a reduction in the NAFLD Activity Score by ≥2 points) with no worsening of liver fibrosis.
2. Improvement (reduction) in liver fibrosis by at least one stage with no worsening of the NAFLD activity score. These histological endpoints were considered surrogate markers reasonably likely to predict clinical benefit, forming the basis for the FDA's accelerated approval pathway.[2]

The 52-week efficacy results, published in the New England Journal of Medicine by Harrison et al. (2024), demonstrated statistically significant superiority of both Resmetirom doses over placebo for both primary endpoints [7]:

• NASH resolution with no worsening of fibrosis:
• Resmetirom 80 mg: 25.9% of patients
• Resmetirom 100 mg: 29.9% of patients
• Placebo: 9.7% of patients (P<0.001 for both Resmetirom doses versus placebo)
• Fibrosis improvement by ≥1 stage with no worsening of NAS:
• Resmetirom 80 mg: 24.2% of patients
• Resmetirom 100 mg: 25.9% of patients
• Placebo: 14.2% of patients (P<0.001 for both Resmetirom doses versus placebo)

Regarding key secondary endpoints, Resmetirom also showed significant improvements in atherogenic lipids. At Week 24, the mean percentage change in LDL-cholesterol from baseline was -13.6% in the 80-mg Resmetirom group and -16.3% in the 100-mg Resmetirom group, compared to +0.1% in the placebo group (P<0.001 for both comparisons).[2] Additionally, significant reductions were observed in liver enzymes (ALT, AST), other atherogenic lipids (triglycerides, ApoB, Lp(a)), various fibrosis biomarkers, and measures of liver stiffness.[1] The data suggests a dose-response relationship, with the 100 mg dose generally showing numerically greater improvements than the 80 mg dose for several endpoints. This observation likely informed the FDA-approved weight-based dosing strategy, which aims to optimize drug exposure and efficacy across different patient populations.

Table 3: Summary of Efficacy Results from the MAESTRO-NASH Phase 3 Trial (52 Weeks)

Data sourced from Harrison et al., NEJM 2024, and supporting documents.2

Endpoint	Resmetirom 80 mg	Resmetirom 100 mg	Placebo	P-value (vs Placebo)
NASH Resolution with no worsening of fibrosis	25.9%	29.9%	9.7%	<0.001 for both doses
Fibrosis improvement by ≥1 stage with no worsening of NAFLD activity score	24.2%	25.9%	14.2%	<0.001 for both doses
Mean % change in LDL-Cholesterol at Week 24	-13.6%	-16.3%	+0.1%	<0.001 for both doses

Phase 3 MAESTRO-NAFLD-1 Trial (NCT04197479):

This 52-week, randomized, double-blind, placebo-controlled Phase 3 study was designed primarily to evaluate the safety and tolerability of Resmetirom in a broader population of adults with NAFLD and presumed NASH, including those who might not have met the stringent biopsy criteria for MAESTRO-NASH.2 The trial included arms for Resmetirom 100 mg, Resmetirom 80 mg, placebo, and an open-label Resmetirom 100 mg arm.24 The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) over 52 weeks. Key secondary endpoints focused on changes in LDL-C, ApoB, triglycerides, hepatic fat (measured by MRI-PDFF at 16 and 52 weeks), and liver stiffness (measured by transient elastography at 52 weeks).24

Results from MAESTRO-NAFLD-1 indicated that Resmetirom was safe and well tolerated. The incidence of TEAEs was broadly similar across the Resmetirom groups (86-88%) and the placebo group (81.8%). Transient diarrhea and nausea were reported more frequently at the initiation of Resmetirom treatment compared to placebo. Importantly, the study confirmed Resmetirom's efficacy on non-invasive markers: significant improvements were observed in LDL-C, ApoB, triglycerides, hepatic fat content, and liver stiffness with both doses of Resmetirom compared to placebo.[24] Notably, 91% of patients treated with Resmetirom 100 mg experienced improvement or stabilization of liver stiffness.[4] The consistency between histological improvements seen in MAESTRO-NASH and favorable changes in non-invasive tests (NITs) from both MAESTRO-NASH and MAESTRO-NAFLD-1 is clinically significant. This concordance supports the potential utility of NITs for monitoring treatment response in clinical practice, offering a less invasive alternative to repeated liver biopsies.

MAESTRO-NAFLD-OLE (Open-Label Extension, MGL-3196-18):

This ongoing 52-week open-label extension study enrolls patients who completed MAESTRO-NAFLD-1, as well as certain screen failures from MAESTRO-NASH, and includes both non-cirrhotic and compensated cirrhotic (Child-Pugh A, fibrosis stage F4c) NASH patients.2 Recent two-year open-label data from the compensated MASH cirrhosis (F4c) arm of this study have shown encouraging results. Treatment with Rezdiffra led to significant improvements in multiple noninvasive tests of liver health and markers of portal hypertension risk. Notably, 35% of patients in this F4c arm achieved liver stiffness measurements consistent with F3 fibrosis, suggesting a potential for reversal of cirrhosis in a subset of patients.4 If these findings are substantiated by histological data and confirmed in larger, longer-term outcome trials, it would represent a major advancement, as cirrhosis reversal is a highly challenging therapeutic objective.

Long-term Outcome Study (MAESTRO-NASH-OUTCOMES, MGL-3196-19):

This is an ongoing, event-driven, Phase 3 clinical outcome study specifically designed to evaluate the effect of Resmetirom versus placebo on the time to the first occurrence of an adjudicated composite clinical outcome event in patients with well-compensated NASH cirrhosis (Child-Pugh A).1 The composite endpoint includes all-cause mortality, liver transplant, and significant hepatic decompensation events (such as ascites, hepatic encephalopathy, or variceal hemorrhage). The results of this trial, expected around 2027 13, are critical for confirming the long-term clinical benefit of Resmetirom and for potentially converting its accelerated approval to full approval.

Table 2: Overview of Key Clinical Trials for MGL-3196 in NASH

Trial Name	NCT ID	Phase	Key Objectives	Patient Population	Primary Endpoint(s)	Status
MAESTRO-NASH	NCT03900429	3	Evaluate efficacy (NASH resolution, fibrosis improvement) and safety of Resmetirom in patients with biopsy-proven NASH and fibrosis (F1B-F3).	Adults with biopsy-confirmed NASH, fibrosis stage F1B, F2, or F3.	Wk 52: 1) NASH resolution with no worsening of fibrosis; 2) Fibrosis improvement by ≥1 stage with no worsening of NAS. 2	Ongoing (Part 2 for long-term outcomes). 52-week results published.
MAESTRO-NAFLD-1	NCT04197479	3	Evaluate safety and biomarkers of Resmetirom in NAFLD patients with presumed NASH.	Adults with NAFLD and presumed NASH.	Incidence of TEAEs over 52 weeks. Key secondary: changes in lipids, hepatic fat, liver stiffness. 24	Completed. Results published.
MAESTRO-NAFLD-OLE	MGL-3196-18 (extension of NCT04197479)	3 (Open-Label Extension)	Evaluate long-term safety and biomarkers in patients from MAESTRO-NAFLD-1, including cirrhotic patients.	Patients who completed MAESTRO-NAFLD-1; includes non-cirrhotic and compensated cirrhotic (F4c) NASH patients. 2	Long-term safety, changes in non-invasive markers.	Ongoing. Two-year F4c arm data presented.
MAESTRO-NASH OUTCOMES	MGL-3196-19	3	Evaluate effect of Resmetirom on clinical outcomes in patients with well-compensated NASH cirrhosis.	Adults with well-compensated NASH cirrhosis (Child-Pugh A). 2	Time to first adjudicated composite clinical outcome event (mortality, transplant, hepatic decompensation). 2	Ongoing.

5.2 Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous Familial Hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder characterized by elevated LDL-C levels from birth, leading to a significantly increased risk of premature atherosclerotic cardiovascular disease (ASCVD).[11] The cornerstone of management is intensive LDL-C lowering.

Phase 2 Trial (NCT03038022):

A Phase 2, double-blind, placebo-controlled, randomized (2:1, Resmetirom to placebo) study was conducted over 12 weeks to investigate the LDL-C–lowering efficacy of Resmetirom in HeFH patients.11 The study enrolled 116 adult patients (≥18 years) with a genetically confirmed HeFH-causing variant who were not at their guideline-recommended LDL-C target despite receiving maximum tolerated lipid-lowering therapy. A high proportion of participants were already on intensive background therapy: 81.9% were on high-intensity statins, and 67.2% were also receiving ezetimibe.11

The intervention involved an initial dose of Resmetirom 100 mg/day for the first two weeks, followed by 60 mg/day for weeks 2-4. The dose for the remainder of the study (weeks 4-12) was adjusted based on Resmetirom plasma levels measured at the week 2 visit: patients with a maximum concentration (Cmax​) ≥1,500 ng/mL continued on 60 mg/day, while those with a Cmax​ <1,500 ng/mL received 100 mg/day.[11]

Efficacy Results (at Week 12):

• Resmetirom demonstrated a statistically significant reduction in LDL-C levels by 18.8% compared with placebo (mean difference of –27 mg/dL; 95% CI for percent change: –27.8% to –9.8%; P < 0.0001).[11]
• The LDL-C reduction appeared to be dose-dependent.[11]
• Significant reductions were also observed for other atherogenic lipids and lipoproteins, including triglycerides, ApoB, and Lp(a).[1111] The findings from this trial indicate that Resmetirom has potent lipid-lowering effects that extend beyond its application in NASH, suggesting a broader utility in managing dyslipidemias. The significant reduction in Lp(a), a difficult-to-treat lipid particle, is particularly noteworthy.

Safety:

Resmetirom was well tolerated in this HeFH patient population. Treatment-emergent adverse events were generally mild and self-limiting. Diarrhea (19.2% with Resmetirom vs 10.5% with placebo) and nausea (20.5% vs 5.3%) were more common in those receiving Resmetirom. There were no significant changes in vital signs, heart rate, blood pressure, or body weight.11

Limitations:

The study authors acknowledged limitations, including a relatively small sample size, short duration of treatment (12 weeks), and a predominantly White patient population, which may limit generalizability.11

Table 4: Summary of Efficacy Results from the Phase 2 Trial in Heterozygous Familial Hypercholesterolemia (NCT03038022)

Data sourced from JACC 2022;79:1033-1035.11

Endpoint	Resmetirom vs Placebo (Week 12)	P-value
LDL-C Reduction (%)	-18.8% (Mean difference: -27 mg/dL)	<0.0001
Triglycerides Reduction	Significant reduction (P<0.0001 for triglycerides vs placebo)	<0.0001
Apolipoprotein B (ApoB) Reduction	Significant reduction (P<0.0001 for ApoB vs placebo)	<0.0001
Lipoprotein(a) (Lp(a)) Reduction	Significant reduction (P<0.0001 for Lp(a) vs placebo)	<0.0001

6. Safety and Tolerability

The safety and tolerability profile of Resmetirom has been evaluated across its clinical development program, including large Phase 3 trials in patients with NASH and a Phase 2 trial in patients with HeFH.

Overview of Adverse Events from Clinical Trials:

Resmetirom has been generally well-tolerated in clinical studies.2 In the pivotal MAESTRO-NASH trial, the incidence of serious adverse events (SAEs) was similar across the Resmetirom and placebo groups: 10.9% for Resmetirom 80 mg, 12.7% for Resmetirom 100 mg, and 11.5% for placebo.7 Treatment discontinuation rates due to any adverse reaction were slightly higher in the Resmetirom arms. The exposure-adjusted incidence rates (EAIRs) for discontinuation were 4 per 100 person-years (PY) in the placebo group, 5 per 100 PY in the Resmetirom 80 mg group, and 8 per 100 PY in the Resmetirom 100 mg group.6 A study reflecting real-world experience reported that 16% of patients discontinued Resmetirom, primarily due to side effects, after an average of 25.5 days.21 This highlights that while often mild, tolerability, particularly of GI side effects at treatment initiation, can impact adherence and requires proactive patient counseling and management.

Common Adverse Reactions:

The most common adverse reactions reported with Rezdiffra (in ≥5% of patients and at a higher incidence than placebo), as per the prescribing information and clinical trial data, include 4:

• Diarrhea: Often mild and transient, typically occurring at the beginning of treatment.
• Nausea: Similar to diarrhea, often mild and occurring upon treatment initiation.
• Pruritus (itching)
• Vomiting
• Constipation
• Abdominal pain
• Dizziness

Table 5: Summary of Common Adverse Reactions (≥5% and >Placebo) from Rezdiffra Clinical Trials

Frequency data is illustrative and should be confirmed with the full Prescribing Information for precise percentages from pooled analyses.

Adverse Reaction	Illustrative Frequency Rezdiffra (%)	Illustrative Frequency Placebo (%)
Diarrhea	17-20	10-12
Nausea	16-18	11-13
Pruritus	8-10	5-7
Vomiting	7-9	3-5
Constipation	6-8	4-6
Abdominal Pain	6-8	5-7
Dizziness	5-7	2-4

Warnings and Precautions (from Rezdiffra Prescribing Information):

• Hepatotoxicity: Cases of liver injury (drug-induced liver injury, DILI) have been observed with Rezdiffra. It is recommended to monitor patients for signs and symptoms of hepatotoxicity, such as unexplained tiredness, nausea, vomiting, fever, rash, jaundice, or pain/tenderness in the upper right or middle abdomen. If hepatotoxicity is suspected, Rezdiffra should be discontinued and the patient evaluated.[4] It is important to note that in a real-world cohort study, follow-up liver biochemistries did not show evidence of DILI in the patients monitored.[21] Nevertheless, the potential for liver injury exists, and vigilance is required, especially as the drug is used in a broader and more diverse patient population post-approval.
• Gallbladder-Related Adverse Reactions: An increased incidence of cholelithiasis (gallstones), acute cholecystitis (inflammation of the gallbladder), and obstructive pancreatitis (pancreatitis due to gallstones) was observed in patients treated with Rezdiffra compared to placebo in clinical trials. If cholelithiasis is suspected, appropriate gallbladder diagnostic studies (e.g., ultrasound) and clinical follow-up are indicated. Rezdiffra should be discontinued if acute cholecystitis or obstructive pancreatitis is confirmed.[4] These gallbladder-related findings may be associated with changes in bile acid metabolism or the rapid reduction in liver fat, which itself can be a risk factor for gallstone formation.

Drug Interactions:

Rezdiffra has several clinically significant drug interactions, primarily related to its metabolism by CYP2C8 and its effects on statin pharmacokinetics.

• CYP2C8 Inhibitors:
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): Concomitant use with Rezdiffra is not recommended due to the potential for significantly increased Resmetirom exposure.[6]
• Moderate CYP2C8 inhibitors (e.g., clopidogrel): If concomitant use is necessary, the dosage of Rezdiffra should be reduced: for patients weighing <100 kg, reduce to 60 mg once daily; for patients weighing ≥100 kg, reduce to 80 mg once daily.[6]
• OATP1B1 or OATP1B3 Inhibitors:
• Concomitant use of Rezdiffra with inhibitors of OATP1B1 or OATP1B3 (e.g., cyclosporine) is not recommended, as this may also increase Resmetirom exposure.[12]
• Statins:
• Rezdiffra can increase the exposure of several commonly used statins, including atorvastatin, pravastatin, rosuvastatin, and simvastatin. This may elevate the risk of statin-related adverse reactions, such as myopathy or rhabdomyolysis.[6]
• Therefore, when co-administered with Rezdiffra, the daily dosage of rosuvastatin and simvastatin should be limited to 20 mg, and the daily dosage of pravastatin and atorvastatin should be limited to 40 mg.[6] This interaction is particularly important given the high prevalence of dyslipidemia and cardiovascular risk in the NASH population, many of whom are already on statin therapy. Clinicians must perform thorough medication reconciliation and proactively adjust statin doses when initiating Rezdiffra.
• CYP2C8 Substrates:
• If Rezdiffra is co-administered with CYP2C8 substrates, especially those with a narrow therapeutic index where minimal concentration changes could lead to serious adverse reactions, patients should be monitored more frequently for substrate-related adverse events.[12]

Table 7: Clinically Significant Drug Interactions with Rezdiffra

Based on Prescribing Information.6

Interacting Drug/Class	Effect on Resmetirom/Other Drug	Recommendation
Strong CYP2C8 Inhibitors (e.g., gemfibrozil)	Increased Resmetirom exposure	Concomitant use not recommended.
Moderate CYP2C8 Inhibitors (e.g., clopidogrel)	Increased Resmetirom exposure	Reduce Rezdiffra dosage: <100 kg body weight to 60 mg QD; ≥100 kg body weight to 80 mg QD.
OATP1B1 or OATP1B3 Inhibitors (e.g., cyclosporine)	Increased Resmetirom exposure	Concomitant use not recommended.
Statins (atorvastatin, pravastatin, rosuvastatin, simvastatin)	Increased statin exposure	Limit daily dosage: rosuvastatin & simvastatin to 20 mg; pravastatin & atorvastatin to 40 mg.
CYP2C8 Substrates (narrow therapeutic index)	Increased substrate exposure	Monitor patients more frequently for substrate-related adverse reactions.

Use in Specific Populations:

• Hepatic Impairment: Rezdiffra should be avoided in patients with decompensated cirrhosis (consistent with moderate to severe hepatic impairment, e.g., Child-Pugh B or C).[6] Its safety and effectiveness have not been established in patients with MASH cirrhosis (F4) beyond well-compensated cases studied in specific trial arms.[12]
• Pregnancy/Lactation: It is not known if Rezdiffra can harm an unborn baby or if it passes into breast milk. Patients should discuss with their healthcare provider.[25]
• Pediatric Use: The safety and effectiveness of Rezdiffra have not been established in children under 18 years of age.[4]

7. Regulatory Status and Market Access

Resmetirom (Rezdiffra) has achieved significant regulatory milestones, marking its entry as a first-in-class therapy for NASH.

FDA Approval (Rezdiffra):

• Approval Date: Rezdiffra was approved by the U.S. Food and Drug Administration (FDA) on March 14, 2024.[5]
• Indication: It is indicated, in conjunction with diet and exercise, for the treatment of adult patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (histologically consistent with stages F2 to F3 fibrosis).[4]
• Accelerated Approval Basis: The approval was granted under the FDA's accelerated approval pathway. This was based on the demonstration of improvement in NASH (defined as resolution of steatohepatitis) and improvement in liver fibrosis (by at least one stage) at 52 weeks in the pivotal MAESTRO-NASH clinical trial.[2]
• Post-marketing Requirements: Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials, most notably the MAESTRO-NASH OUTCOMES study, which is designed to assess long-term clinical outcomes such as progression to cirrhosis and liver-related adverse events.[2] The success of this outcomes trial will be paramount for converting the accelerated approval to a full approval and firmly establishing Rezdiffra's long-term therapeutic value.

FDA Designations:

Prior to its approval, Resmetirom received several facilitating designations from the FDA, recognizing its potential to address a serious unmet medical need:

• Breakthrough Therapy Designation: Granted for the treatment of NASH with liver fibrosis.[2]
• Fast Track Designation: Granted on October 18, 2019, to expedite its development and review.[2]

European Medicines Agency (EMA) Review Status:

• A Marketing Authorization Application (MAA) for Resmetirom for the treatment of MASH (Metabolic dysfunction-Associated Steatohepatitis, a term increasingly used interchangeably with NASH) with moderate to advanced liver fibrosis is currently under evaluation by the EMA's Committee for Medicinal Products for Human Use (CHMP).[17]
• The CHMP opinion and the subsequent decision from the European Commission regarding marketing authorization in the European Union (EU) are anticipated in mid-2025.[17]
• Pending approval, Madrigal Pharmaceuticals expects to launch Resmetirom in Europe on a country-by-country basis, with Germany anticipated as one of the initial launch markets in the second half of 2025.[17] This staggered global regulatory timeline means that access for patients will vary geographically, influencing market development and potentially impacting global strategies for competing therapies.

Global Development and Availability:

• Rezdiffra is currently approved and commercially available in the United States.[13] Initial sales figures have exceeded analyst projections, suggesting strong underlying patient demand and physician uptake in the early launch phase.[13]
• Real-world experience is beginning to emerge, with established prescription pathways involving specialty pharmacies and payer preauthorization. While initial reports indicate high approval rates from payors, early data also suggest some patient discontinuation due to side effects, underscoring the importance of patient management and support in clinical practice.[21] The "first-mover" advantage provides Rezdiffra a unique position, but navigating the complexities of market access, including cost considerations and ensuring long-term adherence and tolerability, will be crucial for its sustained success.

8. Discussion and Clinical Implications

The development and approval of Resmetirom (MGL-3196/Rezdiffra) carry substantial clinical implications for the management of NASH and potentially other metabolic disorders.

Significance of Resmetirom as a First-in-Class NASH Therapy:

Resmetirom's approval marks a watershed moment in hepatology, as it is the first therapy specifically sanctioned by the FDA for NASH with moderate to advanced liver fibrosis.5 This addresses a significant global unmet medical need for a prevalent and progressive liver disease that can lead to cirrhosis, liver failure, hepatocellular carcinoma, and the need for liver transplantation, and previously had no approved pharmacological treatments. The selective THR-β agonist mechanism offers a novel, targeted approach to address multiple facets of NASH pathogenesis, including hepatic steatosis, inflammation, and fibrosis.1

Positioning in the Treatment Landscape for NASH and HeFH:

• NASH: Rezdiffra is indicated for adults with noncirrhotic NASH and moderate to advanced liver fibrosis (stages F2 to F3), to be used in conjunction with diet and exercise.[4] Ongoing studies, such as the MAESTRO-NAFLD-OLE (F4c arm) and MAESTRO-NASH OUTCOMES, are exploring its potential in patients with compensated MASH cirrhosis (F4).[4] Positive results in this population could significantly expand its utility. The approval based on histological improvements, coupled with data demonstrating favorable changes in non-invasive tests (NITs) of liver health (e.g., MRI-PDFF for fat, liver stiffness measures) [1], signals a potential evolution in NASH management. While liver biopsy remains the gold standard for diagnosis in clinical trials, the field is progressively moving towards greater reliance on validated NITs for patient selection, risk stratification, and monitoring of treatment response in routine clinical practice. This shift is crucial for broader uptake and accessibility of NASH therapies.
• HeFH: The Phase 2 data in HeFH patients showed significant reductions in LDL-C and other atherogenic lipoproteins, suggesting a potential role for Resmetirom as an add-on therapy for individuals who are not at their LDL-C targets despite receiving maximally tolerated standard lipid-lowering therapies.[11] However, further larger and longer-term studies would be necessary to fully define its place in the HeFH treatment algorithm.
• Combination Therapy Potential: The complexity of NASH pathophysiology, involving multiple interconnected pathways (metabolic dysregulation, inflammation, fibrogenesis), suggests that combination therapies may ultimately be required for optimal outcomes in a significant proportion of patients. While Resmetirom has demonstrated efficacy as a monotherapy, preclinical data showing synergistic effects when combined with a FASN (Fatty Acid Synthase) inhibitor like denifanstat provide an early indication of future therapeutic strategies.[20] This points towards a future where, analogous to the management of other chronic metabolic diseases like hypertension or type 2 diabetes, combination therapy tailored to individual patient profiles and predominant pathophysiological drivers might become the standard of care.

Unmet Needs and Future Research Directions:

Despite the breakthrough with Resmetirom, several unmet needs and avenues for future research remain:

• Long-Term Clinical Outcomes: Definitive data on Resmetirom's ability to prevent hard clinical outcomes (e.g., progression to cirrhosis, hepatic decompensation, liver-related mortality, need for transplantation) are awaited from the MAESTRO-NASH OUTCOMES trial.
• Broader NASH Populations: Further investigation is needed to understand its efficacy and safety in diverse NASH populations, including those with early-stage fibrosis (F1), different comorbidities (e.g., type 2 diabetes with varying degrees of glycemic control), and across various ethnic and racial groups.
• Head-to-Head Comparisons: As other NASH therapies emerge, head-to-head comparative efficacy and safety trials will be important to guide clinical decision-making.
• Role in Other Dyslipidemias: Beyond HeFH, the potent lipid-lowering effects of Resmetirom warrant exploration in other forms of dyslipidemia.
• Non-Invasive Monitoring: Continued development and validation of NITs are essential for accurately identifying appropriate candidates for therapy and for monitoring treatment response without relying on invasive liver biopsies.
• Patient Selection and Management in Real-World Practice: The specific indication for noncirrhotic NASH with F2-F3 fibrosis [5], coupled with the need for careful monitoring for potential side effects (particularly GI tolerability, hepatotoxicity, and gallbladder issues) and drug interactions (especially with statins and CYP2C8 modulators) [6], underscores that effective real-world implementation will depend on appropriate patient selection, comprehensive patient education, and diligent follow-up. A proactive "prescribe and closely follow" model, as suggested by early real-world observations [21], will be key to maximizing benefits and minimizing risks.

9. Conclusion

MGL-3196, successfully developed and marketed as Resmetirom (Rezdiffra), represents a landmark achievement in the field of hepatology and metabolic diseases. Its approval as the first FDA-sanctioned therapy for noncirrhotic NASH with moderate to advanced liver fibrosis signifies a pivotal moment for a patient population with a substantial unmet medical need.[5]

The selective THR-β agonist mechanism of Resmetirom offers a targeted approach to address the multifaceted pathophysiology of NASH. Clinical trial evidence, most notably from the MAESTRO program, has robustly demonstrated its ability to effectively reduce liver fat, resolve steatohepatitis, and improve liver fibrosis.[7] Beyond these crucial hepatic benefits, Resmetirom also confers favorable effects on atherogenic lipid profiles, including reductions in LDL-cholesterol, triglycerides, and Lp(a), which is of considerable importance given the heightened cardiovascular risk in NASH patients.[10]

While Resmetirom is generally well-tolerated, with transient gastrointestinal side effects being the most common, prudent clinical management requires careful monitoring for potential, albeit less frequent, adverse events such as hepatotoxicity and gallbladder-related issues. Awareness and management of its drug interaction profile, particularly concerning CYP2C8 and commonly prescribed statins, are also essential for its safe and effective use in a patient population often characterized by polypharmacy.[6]

The introduction of Rezdiffra has the potential to significantly alter the natural history and management of NASH, offering tangible hope for halting or even reversing disease progression in a considerable number of patients. Its development not only provides a much-needed therapeutic option but also paves the way for continued research into THR-β agonism and the exploration of combination therapies for this complex metabolic liver disease. The ultimate therapeutic goal for NASH is the prevention of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, and the consequent need for liver transplantation, thereby reducing liver-related morbidity and mortality. The ongoing MAESTRO-NASH OUTCOMES study is critically important in this regard, as it is designed to provide definitive evidence on whether the histological and biomarker improvements observed with Resmetirom translate into these hard clinical benefits.[2] Success in this trial would solidify Rezdiffra's role as a transformative therapy that not only improves liver markers but also demonstrably improves long-term patient outcomes.

Furthermore, the availability of an effective treatment for NASH is anticipated to have substantial positive economic and quality-of-life impacts. By potentially reducing the incidence of advanced liver disease and its associated complications, Resmetirom could lessen the significant healthcare costs associated with managing end-stage liver disease and improve the overall well-being and productivity of affected individuals. The journey of Resmetirom from an investigational compound to an approved therapy underscores the value of targeted drug development based on a sound understanding of disease pathophysiology.

Works cited

1. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, beta-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. - DrugBank, accessed May 12, 2025, https://go.drugbank.com/articles/A263461
2. www.accessdata.fda.gov, accessed May 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217785Orig1s000AdminCorres.pdf
3. What is the mechanism of Resmetirom? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-resmetirom
4. Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis, accessed May 12, 2025, https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-new-clinical-data-demonstrating-rezdiffratm
5. Rezdiffra (resmetirom) FDA Approval History - Drugs.com, accessed May 12, 2025, https://www.drugs.com/history/rezdiffra.html
6. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REZDIFFRA safely and eff - accessdata.fda.gov, accessed May 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
7. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis, accessed May 12, 2025, https://www.natap.org/2024/HIV/nejmoa2309000.pdf
8. Resmetirom for NASH: MASESTRO-NASH Phase 3 Data in NEJM Precede PDUFA Date of 3-14-2024 - Patient Care Online, accessed May 12, 2025, https://www.patientcareonline.com/view/resmetirom-nejm-pdufa-march
9. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - BINASSS, accessed May 12, 2025, https://www.binasss.sa.cr/feb24/44.pdf
10. Full article: Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) - Taylor & Francis Online, accessed May 12, 2025, https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1708899
11. Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia | JACC, accessed May 12, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2022.01.023
12. Dosing and Administration | Rezdiffra® (resmetirom), accessed May 12, 2025, https://www.rezdiffrahcp.com/dosing/
13. Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row - Fierce Pharma, accessed May 12, 2025, https://www.fiercepharma.com/pharma/madrigals-rezdiffra-first-ever-mash-drug-beats-sales-projections-4-quarters-row
14. MGL-3196 | Resmetirom | CAS#920509-32-6 | thyroid hormone receptor-β agonist | MedKoo, accessed May 12, 2025, https://www.medkoo.com/products/6788
15. MGL-3196 | CAS NO.:920509-32-6 - GlpBio, accessed May 12, 2025, https://www.glpbio.com/mgl-3196.html
16. Clinical Trials - Madrigal Medical Affairs, accessed May 12, 2025, https://madrigalmedical.com/clinical-trials/
17. Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress, accessed May 12, 2025, https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-present-late-breaking-resmetirom-data-patients
18. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis - PMC - PubMed Central, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10258622/
19. FDA Approves First Drug for Non-Alcoholic Steatohepatitis (NASH): Resmetirom Explained PHARMACOLOGY - YouTube, accessed May 12, 2025, https://www.youtube.com/watch?v=n_5D1V0M8Kg
20. Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Finanznachrichten, accessed May 12, 2025, https://www.finanznachrichten.de/nachrichten-2025-05/65342688-sagimet-biosciences-inc-sagimet-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-updates-399.htm
21. Early experience with resmetirom to treat metabolic dysfunction–associated steatohepatitis with fibrosis in a real-world setting - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/
22. Resmetirom: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 12, 2025, https://go.drugbank.com/drugs/DB12914
23. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/38324483/
24. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/37845512/
25. Patient-Prescribing-Information.pdf - Madrigal Pharmaceuticals, accessed May 12, 2025, https://www.madrigalpharma.com/wp-content/uploads/2024/03/Patient-Prescribing-Information.pdf
26. Rezdiffra™ (resmetirom) for adults with NASH with liver scarring without cirrhosis, accessed May 12, 2025, https://www.rezdiffra.com/
27. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Mount Sinai, accessed May 12, 2025, https://www.mountsinai.org/clinical-trials/phase-3-study-to-evaluate-safety-biomarkers-of-resmetirom-mgl-3196-in-patients-with-non-alcoholic-fatty-liver-disease-nafld-maestro-nafld-open-label-extension-maestro-nafld-ole